Current worldwide challenges in scaling COVID19 diagnosis underscore the need for developing inexpensive point-of-care diagnostics for infectious diseases. The heterogeneity of the disease – a large number of mild or asymptomatic cases coupled with the rapid degradation in symptoms in some patients – pose a challenge for the healthcare system and emphasize the need for developing predictive biomarkers of disease severity. We are harnessing microscale technology to solve these challenges by developing devices for high-throughput discovery and inexpensive electronic detection of biomarkers. Here, I will present our progress with these approaches – in the context of Tuberculosis and other infectious diseases – and end by outlining our current work in applying them to COVID19 diagnosis and prognostic monitoring.